Search results
Theriva Biologics Receives Fast Track Designation From FDA For VCN-01 For Treating Metastatic...
Benzinga· 6 days agoTheriva™ Biologics TOVX is an immuno-oncology company developing oncolytic viruses, otherwise known...
Small Business - Picayune Item | Picayune Item
The Picayune Item· 4 days agoCalyx / Invicro Forges a Strategic Collaboration with BAMF Health to Accelerate Clinical Translation of Radioligand Therapies and Immuno-Oncology Agents ...
AbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab...
The Parsons Sun· 6 days agoPICCOLO trial met its primary endpoint of objective response rate (ORR)Data from the study will be presented at a future medical meeting
Fundraiser for Pelotonia to Take Place at the Downtown Exchange - WHIZ - Fox 5 / Marquee...
WHIZ News Zanesville· 9 hours agoJames Cancer Hospital and Richard J. Solove Research Institute, and the Pelotonia Institute for ...
Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024
Morningstar· 7 days agoAffimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced ...
Replimune (REPL) Gains on Positive Data From Melanoma Study
Zacks via Yahoo Finance· 5 days agoReplimune's (REPL) lead pipeline candidate RP1, in combination with Opdivo, leads to an overall...
Agenus (NASDAQ:AGEN) Stock Crosses Above 200-Day Moving Average of $12.95
ETF DAILY NEWS· 1 day agoAgenus Inc. (NASDAQ:AGEN – Get Free Report) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $12.95 and traded as high as $17.65.
Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought
The Motley Fool via AOL· 3 days agoAnd it's key because it represents a source of revenue. Meanwhile, CRISPR Therapeutics is moving...
This Needham biotech's stock has gone up 700% in 3 months - Boston Business Journal
The Business Journals· 2 days agoPaul Peter Tak, CEO of the immuno-oncology company, recently sat down with the Business Journal to...
Phio Pharmaceuticals (NASDAQ:PHIO) Stock Price Up 2.5%
ETF DAILY NEWS· 5 days agoPhio Pharmaceuticals Corp. (NASDAQ:PHIO – Get Free Report) rose 2.5% during trading on Thursday . The company traded as high as $0.75 and last traded at $0.74. Approximately 10,152 shares traded ...
